Open-label safety study to evaluate imiquimod cream, 5% for large areas of actinic keratosis.(CLINICAL TRIAL REVIEW) From: Journal of Drugs in Dermatology | Date: February 1, 2006 | COPYRIGHT 2006 Journal of Drugs in Dermatology, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group.Copyright information

This study is currently recruiting patients. Sponsored by: 3M Pharmaceuticals. The purpose of this study is to evaluate the safety of one, two, or three cycles of imiquimod for the treatment of AK. The AK lesions treated can be in adjacent and nonadjacent areas of the head, torso, and extremities. Th...

Related newspaper, magazine, and journal articles from HighBeam Research

	Open-label safety study to evaluate imiquimod cream 5% for large areas of AK.(CLINICAL TRIAL REVIEW) Journal of Drugs in Dermatology ; This study is currently recruiting patients. Sponsored by 3M Pharmaceuticals. The purpose of this study is to evaluate the safety of one, two, or three cycles of imiquimod for the treatment of AK. Condition Treatment or Intervention Phase Keratosis Drug: imiquimod cream Phase IV Study ID Numbers:
	New indications Formulary ; Aldara Imiquimod cream, 5% 3M PHARMACEUTICALS Immune response modifier approved for superficial basal cell carcinoma Although the mechanism of action of imiquimod is unknown, an open-label study suggests that the drug may act by increasing the filtration of lymphocytes, dendritic cells, and
	Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals.(WASHINGTON WHISPERS) Journal of Drugs in Dermatology ; Imiquimod Cream 5% for Recalcitrant Cutaneous Warts in Immunosuppressed Individuals Harwood CA, MD et al. British Journal of Dermatology. 2005;152:122-129. Summary The authors present an open-label, left versus right comparison study on the efficacy of imiquimod cream in the treatment of
	Scar cosmesis Dermatology Times ; Imiquimod may be effective as surgical adjunct Las Vegas - Results from clinical trials suggest the topical immune response modifier imiquimod 5 percent cream (Aldara, Graceway Pharmaceuticals) may be a useful adjunct in the surgical management of keloids and basal cell carcinoma (BCC), says Brian
	Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis.(WASHINGTON WHISPERS) Journal of Drugs in Dermatology ; Dosing with 5% Imiquimod Cream 3 Times per Week for the Treatment of Actinic Keratosis Korman N, MD, et al. Archives of Dermatology. 2005;141:467-473. Summary The authors present 2 phase 3, multi-center, randomized, double-blind, vehicle-controlled trials to evaluate the efficacy and safety of

See all results.